Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | TAF1 | P21675 | 1/20 | 0.36 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22290078 | 0.74 | BRD9 (0.39) | BRD9BRD4TAF1BRPF1CREBBP | |
| SCHEMBL16942511 | 0.72 | BRD9 (0.40) | BRD9BRD4TAF1BRPF1CREBBP | |
| SCHEMBL22290086 | 0.68 | BRD9 (0.36) | BRD9BRD4TAF1BRPF1CREBBP | |
| SCHEMBL29518567 | 0.68 | BRD9 (0.36) | BRD9BRD4TAF1BRPF1CREBBP | |
| SCHEMBL9881469 | 0.64 | BRD9 (0.33) | BRD9BRD4TAF1BRPF1CREBBP | |
| SCHEMBL1833677 | 0.60 | FDPS (0.41) | HRH3LMNATAAR1ALDH1A1ALOX15 | |
| SCHEMBL20840569 | 0.59 | HRH3 (0.52) | HRH3LMNATAAR1ALDH1A1ALOX15 | |
| SCHEMBL10005837 | 0.59 | BRD4 (0.42) | BRD9BRD4TAF1BRPF1CREBBP | |
| SCHEMBL10050973 | 0.59 | BRD9 (0.42) | BRD9BRD4TAF1BRPF1CREBBP | |
| SCHEMBL1623247 | 0.59 | BRD9 (0.39) | BRD9BRD4TAF1BRPF1CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384776-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20220098190-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2022-03-31 | — | — | US | disclosed |
| EP-3917529-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160196-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160196-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098190-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | BRD9 290/4885BRD4 42/4885TAF1 293/4885 |
| US-12384776-B2 | Compounds and uses thereof | VHL, TFEB, BECN1 | BRD9 290/4885BRD4 42/4885TAF1 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.